Eli Lilly and Company
LLYHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Eli Lilly and Company focuses on Drug Manufacturers - General services and products. Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. At a $1.05T market cap, Eli Lilly and Company ranks as a mega-cap company within healthcare. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Market Cap
$1.05T
Beta
0.51
P/E (TTM)
41.49
P/E (Fwd)
26.25
EPS (TTM)
$28.42
EPS (Fwd)
$44.91
ROE
107.5%
ROA
20.7%
Cash
$5.28B
Total Debt
$43.37B
Free CF
$9.16B
52W Change
52.8%
Annual Financials
Cash vs Debt
The company holds $5.28B in cash, though total debt stands at $43.37B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $9.16B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 107.5% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 20.7% further supports the picture of efficient asset utilization. Revenue has grown from $28.54B (2022) to $65.18B (2025), reflecting a 128% increase over the period.
With a beta below 0.7, Eli Lilly and Company typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. No single metric tells the full story. Reviewing LLY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.